BRIEF published on 07/28/2025 at 07:35, 1 year ago MaaT Pharma Secures €37.5 Million Loan to Boost Hemato-Oncology Programs Clinical Development EIB Loan Hemato-oncology Microbiome Therapy Xervyteg® Approval
PRESS RELEASE published on 07/28/2025 at 07:30, 1 year ago Inside Information / Other news releases MaaT Pharma secures €37.5 million loan from the European Investment Bank to advance clinical programs in Hemato-Oncology. Funding supports late-stage assets Xervyteg® and MaaT033 European Investment Bank Clinical Programs Loan MaaT Pharma Hemato-oncology
BRIEF published on 06/24/2025 at 20:05, 1 year 1 month ago MaaT Pharma General Meeting: Results and Appointments Kepler Cheuvreux Resolutions General Assembly MaaT Pharma Appointment Of President
PRESS RELEASE published on 06/24/2025 at 20:00, 1 year 1 month ago Inside Information / Other news releases MaaT Pharma presents Annual General Meeting results, with shareholders approving most resolutions. Jean-Marie Lefevre appointed Chairman. Liquidity contract with Kepler Cheuvreux maintained Annual General Meeting Shareholders Liquidity Contract MaaT Pharma Jean-Marie Lefevre
BRIEF published on 06/19/2025 at 19:05, 1 year 1 month ago MaaT Pharma Advances Xervyteg® Commercialization Efforts European Market Clinical Trials Oncology Microbiome Xervyteg®
PRESS RELEASE published on 06/19/2025 at 19:00, 1 year 1 month ago Inside Information / Other news releases MaaT Pharma provides business update & highlights key milestones for 2025, including MA application submission for Xervyteg, strategic focus in Europe & US trial launch Business Update Clinical-stage Biotechnology MaaT Pharma Key Milestones Xervyteg
BRIEF published on 06/13/2025 at 07:35, 1 year 1 month ago MaaT Pharma Reveals Promising Data for Xervyteg® at EHA Congress Clinical Efficacy Safety Profile Xervyteg® AGvHD EMA Application
PRESS RELEASE published on 06/13/2025 at 07:30, 1 year 1 month ago Inside Information / Other news releases MaaT Pharma presents updated positive data for Xervyteg® in treating acute Graft-versus-Host Disease at EHA Congress, validating high efficacy observed in pivotal ARES study MaaT Pharma Acute Graft-versus-Host Disease EMA Approval Xervyteg EAP Data
BRIEF published on 05/12/2025 at 07:35, 1 year 2 months ago Promising data for MaaT033 in ALS Microbiome Amyotrophic Lateral Sclerosis MaaT033 Safety And Tolerability Phase 1b Clinical Trial
BRIEF published on 04/08/2025 at 07:35, 1 year 3 months ago MaaT Pharma Announces Positive Interim Safety Results for MaaT033 Phase 2B Trial MaaT Pharma MaaT033 Allo-HSCT DSM Safety
Published on 08/04/2026 at 22:30, 2 hours ago Nextech3D.ai Provides Update on Acquisition of Remaining ARway Shares
Published on 08/04/2026 at 16:25, 8 hours 5 minutes ago ACCESS Newswire to Host Second Quarter Earnings Conference Call on August 11, 2026
Published on 08/04/2026 at 15:00, 9 hours 30 minutes ago Infield Minerals Expands Land Position at the Kings Canyon Gold Project in Utah
Published on 08/04/2026 at 15:00, 9 hours 30 minutes ago Secure Blockchain's Agentic Solutions Signs First Enterprise AI Customer
Published on 08/04/2026 at 22:03, 2 hours 26 minutes ago #FutureFresenius: Excellent Q2 performance demonstrates structural step-up – Guidance raised
Published on 08/04/2026 at 22:01, 2 hours 29 minutes ago EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius raises its earnings guidance for fiscal year 2026 due to strong operational business performance
Published on 08/04/2026 at 20:05, 4 hours 25 minutes ago Hard Rock Cafe and Coca-Cola® Launch Hard Rock Rising Music Competition for Emerging Artists
Published on 08/04/2026 at 19:39, 4 hours 50 minutes ago EQS-Adhoc: Basler AG financial results for the first 6 months of 2026: Strong business performance in the first half of the year; company raises its 2026 forecast once again
Published on 08/04/2026 at 18:32, 5 hours 57 minutes ago Total number of voting rights and shares making up the share capital at July 31, 2026
Published on 08/04/2026 at 17:45, 6 hours 45 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 08/04/2026 at 16:00, 8 hours 30 minutes ago MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 08/04/2026 at 08:15, 16 hours 15 minutes ago Covivio - Conditions of availability of the 2026 Half-year report
